Coronary Artery Disease (CAD) - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 113

Coronary Artery Disease (CAD) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Coronary Artery Disease (CAD) - Pipeline Review, H1 2012', provides an overview of the Coronary Artery Disease (CAD) therapeutic pipeline. This report provides information on the therapeutic development for Coronary Artery Disease (CAD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD). 'Coronary Artery Disease (CAD) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Coronary Artery Disease (CAD).
- A review of the Coronary Artery Disease (CAD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Coronary Artery Disease (CAD) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) pipeline depth and focus of Coronary Artery Disease (CAD) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Coronary Artery Disease (CAD) Therapeutic Products under Development, Key Players in Coronary Artery Disease (CAD) Therapeutics, Coronary Artery Disease (CAD) Pipeline Overview, Coronary Artery Disease (CAD) Pipeline, Coronary Artery Disease (CAD) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coronary Artery Disease (CAD) Overview
Therapeutics Development
An Overview of Pipeline Products for Coronary Artery Disease (CAD)
Coronary Artery Disease (CAD) Therapeutics under Development by Companies
Coronary Artery Disease (CAD) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Coronary Artery Disease (CAD) Therapeutics – Products under Development by Companies
Coronary Artery Disease (CAD) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Coronary Artery Disease (CAD) Therapeutics Development
Bristol-Myers Squibb Company
Cardium Therapeutics, Inc.
Isis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
CardioVascular BioTherapeutics, Inc.
Glenmark Pharmaceuticals Ltd.
Japan Tobacco Inc.
Momenta Pharmaceuticals, Inc.
Resverlogix Corp.
Evolva SA
Pervasis Therapeutics, Inc.
Phage Biotechnology Corporation
Viromed Co., Ltd.
Ischemix
Coronary Artery Disease (CAD) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-0859 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XL652 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JTT705 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Generx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-077 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RVX-208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cangrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemopure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vascugel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMX-2043 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HOE 140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AndroGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Efient - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Telmisartan + Bisoprolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clopidogrel + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prasugrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Landiolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Coenzyme Q10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eicosapentaenoic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GBR 600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amiloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endocardial Adenovirus VEGF-D Gene Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neo-Vessel Replacement - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LDE-Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-CRP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACP-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Coronary Artery Disease (CAD) Therapeutics – Drug Profile Updates
Coronary Artery Disease (CAD) Therapeutics – Discontinued Products
Coronary Artery Disease (CAD) Therapeutics - Dormant Products
Coronary Artery Disease (CAD) – Product Development Milestones
Featured News & Press Releases
Mar 30, 2012: AlphaCore Pharma Initiates Phase I Study Of ACP-501 In Patients With Coronary Artery Disease
Mar 02, 2012: BioInvent Completes Recruitment Of Patients In Phase II Study With BI-204
Dec 15, 2011: CHMP Adopts Positive Opinion Recommending Granting Of Marketing Authorization For Corlentor
Nov 16, 2011: New Analysis Of Data Presented At AHA Shows Effects Of Effient On Cardiovascular Events In STEMI Patients
Nov 10, 2011: Ablynx Reports Phase II Data For ALX-0081 In High Risk Acute Coronary Syndrome Patients Undergoing PCI Procedure
Nov 02, 2011: Resverlogix Commences Dosing In ASSURE Phase IIb IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
Sep 21, 2011: Health Canada Provides Update On Trasylol
Aug 29, 2011: Roche Announces Results From Two Exploratory Phase IIb Studies Of Dalcetrapib
Jun 08, 2011: Acusphere Reaches Special Protocol Assessment Agreement With FDA For Imagify Phase III Placebo-Controlled Trial
Mar 29, 2011: Effient Added To Updated ACCF/AHA Clinical Guidelines For ACS-PCI Patients With Unstable Angina And Non-ST Segment Myocardial Infarction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Coronary Artery Disease (CAD), H1 2012
Products under Development for Coronary Artery Disease (CAD) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Cardium Therapeutics, Inc., H1 2012
Isis Pharmaceuticals, Inc., H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
CardioVascular BioTherapeutics, Inc., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Japan Tobacco Inc., H1 2012
Momenta Pharmaceuticals, Inc., H1 2012
Resverlogix Corp., H1 2012
Evolva SA, H1 2012
Pervasis Therapeutics, Inc., H1 2012
Phage Biotechnology Corporation, H1 2012
Viromed Co., Ltd., H1 2012
Ischemix, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Coronary Artery Disease (CAD) Therapeutics – Drug Profile Updates
Coronary Artery Disease (CAD) Therapeutics – Discontinued Products
Coronary Artery Disease (CAD) Therapeutics – Dormant Products
Coronary Artery Disease (CAD) Therapeutics – Dormant Products (Contd..1)
Coronary Artery Disease (CAD) Therapeutics – Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD), H1 2012
Products under Development for Coronary Artery Disease (CAD) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Lung Disease - Pipeline Review, H1 2013
• Candidiasis - Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Acute Coronary Syndrome - Pipeline Review, H2 2012
• Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2012
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Scar - Pipeline Review, H1 2013
• Sarcopenia - Pipeline Review, H1 2013
• Herpes Simplex Infections - Pipeline Review, H1 2013